Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

28.19 +0.47 (+1.70%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viking Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Where Will Viking Therapeutics Be in 3 Years?
Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 billion over the coming years. 
Via The Motley Fool
Topics Bankruptcy
1 Beaten-Down Stock to Buy and Hold for 10 Years
Via The Motley Fool
Topics Economy
Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?
Via The Motley Fool
Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain
Via The Motley Fool
Why Viking Therapeutics Stock Popped Again Today
Cantor Fitzgerald thinks the GLP-1 diet drug VK2735 will be a "multi-blockbuster" for Viking stock. 
Via The Motley Fool
Earnings Scheduled For April 23, 2025
Via Benzinga
Earnings Preview For Viking Therapeutics
Via Benzinga
How Is The Market Feeling About Viking Therapeutics?
Via Benzinga
Why Viking Therapeutics Stock Popped Today
2025 is the year we learn whether Viking Therapeutics stock will be a winner. 
Via The Motley Fool
Viking Therapeutics Stock May Struggle After As-Expected Report
Viking Therapeutics stock is trying to push higher as investors attempt to sort out a report that delivered no real news that investors hadn’t already heard. 
Via MarketBeat
Viking Therapeutics Stock Dips After Q1 EPS Miss: Details
Viking Therapeutics releases its first-quarter results after Wednesday's closing bell. Here's a look at the details from the report. 
Via Benzinga
A Look At Viking Therapeutics VKTX
While we wait for the earnings report to be posted along with the forward guidance predictions, the chart looks interesting. 
Via Talk Markets
Topics Stocks / Equities
Did Eli Lilly Just Say Checkmate to Novo Nordisk?
Via The Motley Fool
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide
Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding. 
Via The Motley Fool
2 Stocks Down by 25% or More This Year to Buy and Hold
Via The Motley Fool
Topics Government
Eli Lilly Stock Rockets On Weight-Loss Pill Progress
Eli Lilly's pill-form weight loss drug cansdidate cleared one of several Phase III hurdles. 
Via Investor's Business Daily
Topics Government
Viking Therapeutics Stock Pops But Struggles to Hold Gains
VKTX stock shot higher after announcing a phase 3 trial for its GLP-1 drug candidate; but investors are concerned about a lack of support in Washington 
Via MarketBeat
Will Pfizer Approach Viking Therapeutics With A Buyout Proposa
Investors are running into Viking Therapeutics this week after an incident of drug-induced liver injury pushed Pfizer into terminating the development of its weight-loss pill. 
Via Talk Markets
Topics Stocks / Equities
Down 71%, Should You Buy the Dip on Viking Therapeutics Stock?
Via The Motley Fool
Wall Street Sees Pfizer's Weight-Loss Pill Exit As A Win For 2 Smaller Biotech Firms: Retail Turns Bullish
Investors are now considering the possibility of Pfizer acquiring either of these companies as it looks for external candidates. 
Via Stocktwits
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today
Pfizer bows, but is not entirely out of the GLP-1 race. 
Via The Motley Fool
What's Going On With Viking Therapeutics, Structure Therapeutics Stock On Monday?
Pfizer ends danuglipron development after liver safety issue, boosting shares of Viking, Eli Lilly, and Novo Nordisk amid obesity drug competition. 
Via Benzinga
Third Harmonic Bio, Apple, Dell And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Pfizer Scraps Obesity Pill After Potential Drug-Tied Liver Injury
The company is continuing to test a daily pill that blocks GIPR. 
Via Investor's Business Daily
3 Magnificent Stocks That Could Double or More by 2030
Via The Motley Fool
Will Viking Therapeutics Be a Top Healthcare Stock in 10 Years?
Via The Motley Fool
The Smartest Biotech Stocks to Buy With $50
Via The Motley Fool
Viking Therapeutics, Down 40%, Just Reached a New Milestone. Is the Stock a Buy Now?
Via The Motley Fool
Which Healthcare Stock Is the Best Buy Right Now?
Healthcare stocks provide a combination of upstarts with a high risk, high reward proposition to established firms that can be a defensive maneuver. 
Via MarketBeat
Viking Therapeutics Skids Despite 'Rapid' Enrollment In Obesity Pill Study
The "rapid" enrollment suggests there's still huge interest in the company's approach to obesity treatment. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
24 25 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.